Tryp Therapeutics Partners with Fluence for Psychotherapy DesignTryp Therapeutics Announces Q2 2021 Financial ResultsRritual Announces CROSSMARK Partnership to Optimize Retail GrowthNuminus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company LabWill The ATAI Life Sciences IPO Bring Investor Interest Back To the Psychedelics Sector?MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During PCybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and AddictionTryp Therapeutics Reports on Key Milestones for 2021Psyched Wellness Receives DTC EligibilityCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicaRritual Appoints Sarton Molnar-Fenton, Vice President Sales USATryp Therapeutics Announces Listing on OTCQB and DTC EligibilityPure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay OffTryp Therapeutics Appoints Greg McKee as Chief Executive OfficerPsyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms andCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United StatesPsyched Wellness Initiates Study on AME-1 Extract for Gut HealthRritual Superfoods to Launch Product Line in Rite Aid Stores – NationwideMushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (

Technical420 Site Search

Returned 25 result(s).

Tryp Therapeutics Partners with Fluence for Psychotherapy Design

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp") a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. Fluence is led by researchers and psychotherapists with…

Tryp Therapeutics Announces Q2 2021 Financial Results

Tryp Therapeutics Inc. (CSE: TRYP), today announced its interim financial results for the three and six month periods ended February 28, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the…

Tryp Therapeutics Reports on Key Milestones for 2021

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, reported today on the Company's significant progress since successfully completing its Initial Public Offering in December 2020. Tryp is advancing two drug development platforms: Psilocybin-for-Neuropsychiatric Disorders (PFNTM) targeting chronic…

Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has appointed Greg McKee as its Chief Executive Officer. Mr. McKee will also continue in his responsibilities as Chairman of the…

MushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)

Over the past year there has been a significant increase in interest in companies that are focused on the psychedelic therapy market--a trend that we are following closely. Interest in these companies has been steadily rising in 2021, and we are focused on identifying businesses that have staying power. Tryp…

Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today that it has submitted a provisional patent (US 63/161,070) to improve how psychedelics are administered across a broad range of indications. The provisional patent describes novel methods for the formulation,…

Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer

Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that it has appointed Luke Hayes as its Chief Financial Officer. Mr. Hayes has been active in the life science…

Tryp Therapeutics Has Been Laser Focused On Executing On Its Business Plan Post Listing

Last month, we highlighted Tryp Therapeutics Inc. (CSE: TRYP) as a hyper-focussed play on the psychedelic biotech market and an opportunity that our readers need to be aware of. So far this year, Tryp has been executing on previously announced growth initiatives and the story has made substantial advancements. TRYP…

Tryp Therapeutics Completes $2 Million Strategic Financing

Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that effective February 16, 2021, it has closed its previously announced financing (see news release February 5, 2021) and issued 3,333,333 million units…

Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program

Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced that Albany Molecular Research ("AMRI") has begun the process of manufacturing the 200g non-GMP demonstration batch of psilocybin. This production step is one of…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link